In a JAMA perspective piece, leading infectious disease researchers call for a coordinated response to HIV and COVID-19 globally, building on the successes of key donor programs such as the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program and Global Fund to Fight AIDS, TB and Malaria (GFATM).
Newly released data from an ongoing research study at the University of Arizona Health Sciences in combination with the Center for Disease Control and Prevention’s PROTECT study show that the Pfizer-BioNTech COVID-19 vaccine has been a moderately effective tool for preventing the spread of COVID-19 and reducing the severity of infection among children and adolescents.
Using mRNA technology like that in the COVID-19 vaccines, researchers have demonstrated a successful way to deliver a potential HIV vaccine, researchers at Duke Human Vaccine Institute report.
The parasites that cause a disfiguring skin disease affecting about 12 million people globally may have met their match in vaccines developed using CRISPR gene-editing technology, new research suggests.
Financial incentives and other nudges have been used to help increase vaccination rates across the nation, but new research from the University of California San Diego’s Rady School of Management reveals that compensations need to be large—at least $100—to reduce vaccine hesitancy.
The first 12 study participants have been enrolled in a new Phase 1 clinical trial using the messenger ribonucleic acid (mRNA) vaccine technology developed by Moderna. The study evaluates the safety of and immune responses to three different experimental vaccines against HIV. This randomized, open-label trial represents one of the first clinical studies of the use of mRNA vaccine technology against HIV.
Briefly blocking a key molecule when administering the only approved vaccine for tuberculosis vastly improves long-term protection against the devastating disease in mice, researchers from Texas Biomedical Research Institute report this week in the Journal of Immunology.
With mask mandates being lifted and case counts dropping, University of Michigan experts reflect on living with ongoing COVID-19.
McMaster researchers have been able to re-engineer red blood cells and use them as a promising new vehicle for vaccine delivery.
They were the first to answer the call in March 2020. Here, several University of Michigan Health faculty and staff members reflect on their personal and professional experiences during the pandemic, sharing hardships most may not have felt or seen outside of the hospital walls.
The antiviral therapies remdesivir, molnupiravir, and the active ingredient in Pfizer’s Paxlovid pill (nirmatrelvir), remain effective in laboratory tests against the BA.2 variant of SARS-CoV-2, the virus that causes COVID-19. The BA.2 variant also remains susceptible to at least some of the monoclonal antibodies used to treat COVID-19, such as Evusheld by AstraZeneca.
mRNA vaccines are highly effective in preventing covid-19 associated hospital admissions related to the alpha, delta, and omicron variants.
The study, led by Moffitt Cancer Center, followed 515 patients with varying cancers. The goal was to evaluate if patients had an immune response to the Moderna mRNA-1273 vaccine and if that response differed by diagnosis and treatment.
By: Bill Wellock | Published: March 10, 2022 | 9:53 am | SHARE: The first COVID cases in the United States were confirmed in early 2020. Since then, the pandemic has raised questions about health care, education, civil rights and responsibilities and more.Florida State University experts are available to talk about the effort to develop vaccines and treatments for COVID-19 and the effects of the pandemic on the hospitality industry.
• Compared with individuals on dialysis who were not vaccinated against COVID-19, those who had received 2 mRNA vaccine doses were 69% and 83% less likely to become infected or experience severe disease, respectively. • There were no significant differences in vaccine effectiveness among age groups, mode of dialysis, or vaccine type.
Don't miss these articles in our Staff Picks channel
SARS-CoV-2 viruses can hide from recognition by the immune system.
Researchers at the Uniformed Services University in collaboration with University of Washington, have recently uncovered new details about how Nipah and Hendra viruses infect cells and the immune responses that can block them, which could ultimately lead to the development of new tactics to prevent and treat these deadly illnesses.
Two years after the early days of the COVID-19 crisis, a case study examines the successful response and leadership role of Rutgers related to vaccination and the safety of faculty, staff and students
With cold and flu season underway, plus the ongoing COVID-19 pandemic, infectious disease specialist Jeffrey Bender, MD, shares how to tell the difference between the illnesses, and the most important thing parents can do to keep children safe.
Following years of growing vaccine opposition and several outbreaks of measles--a vaccine-preventable disease--Facebook established in 2019 its first policy to stop the spread of misinformation about vaccines. Researchers at the George Washington University wondered if the new policies actually worked to stop the spread of misinformation. Jiayan Gu, PhD student along with Lorien Abroms, Professor of Prevention and Community Health and their colleagues created a new paradigm for evaluation of the policy. The team found that Facebook’s policy did reduce people’s interactions with vaccine misinformation.
Nirsevimab showed 74.5 percent efficacy against medically attended lower respiratory tract infections caused by respiratory syncytial virus (RSV) in healthy infants, according to an international, randomised, placebo-controlled Phase 3 clinical trial. It is the first potential immunization against RSV in the general infant population, with a single dose providing safe protection across the entire RSV season. Results were published in the New England Journal of Medicine.
Trauma patients treated and hospitalized in a Tennessee medical center had a 33% lower rate of COVID-19 vaccination than non-trauma patients who were hospitalized following treatment in the emergency department.
Two years after the pandemic began, the virus that causes COVID-19 is becoming a little easier to live with, thanks to medical innovations.
COVID-19 vaccines have been a game-changer in the current pandemic.
Medical research has benefitted from the intense scale, speed and efficiency of COVID-19 studies. Increased funding as well as applied methodologies, proven tools and advanced techniques help scientists stay prepared for emerging diseases and future virus threats.
The largest clinical review of immune responses to paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics, with a focus on infectious diseases, has provided insights into unintended impacts of these commonly used medicines.
A new study using serum from human blood samples suggests neutralizing antibody levels produced by two-dose mRNA vaccines against the original and early variants of the SARS-CoV-2 virus wane substantially over time, and offer essentially no protection against the omicron variant.
The American Association of Colleges of Nursing (AACN) has been awarded $1 million in funding from the Centers for Disease Control and Prevention (CDC) to launch a new initiative titled Building COVID-19 Vaccine Confidence Among Nurses and in Communities. Although COVID-19 vaccines have been widely available for more than a year, only 64% of the US population is fully vaccinated. As part of this project, AACN will award funding to 10 schools of nursing nationwide to launch targeted campaigns to build confidence in the COVID-19 vaccines and dispel health misinformation.
Bangkok, February 10, 2022 – Chulalongkorn University held a Chula the Impact 7 Seminar on “the Progress of Personalized, Therapeutic Cancer Vaccine: An Innovation of Hope for Thai Society” by the CU Cancer Immunotherapy Excellence Center, Faculty of Medicine, and the King Chulalongkorn Memorial Hospital, Thai Red Cross Society, funded by the Second Century Fund, Chulalongkorn University (C2F).
— 妙佑医疗国际(Mayo Clinic)的疫苗研究小组负责人强调，考虑到未来患者的安全性，有必要加强对疫苗及其机制的长期研究。
مدينة روتشستر، ولاية مينيسوتا — أكد قادة مجموعة أبحاث اللقاحات في مايو كلينك على الحاجة لإجراء دراسة طويلة الأمد على اللقاحات وآلياتها مع الوضع في الاعتبار سلامة المرضى في المستقبل.
Los directores del Grupo de Investigación sobre Vacunas en Mayo Clinic resaltan la necesidad de llevar a cabo estudios a largo plazo sobre las vacunas y sus mecanismos, con la mira puesta en la futura seguridad de los pacientes.
Os líderes do Grupo de Pesquisa em Vacinas da Mayo Clinic enfatizam a necessidade de aumentar os estudos de longo prazo das vacinas e seus mecanismos pensando na segurança futura dos pacientes.
A Stony Brook University physician-scientist has identified that mucosal-associated invariant T (MAIT) cells exercise several complex roles during healthy and disease states. The published findings may help to serve as a benchmark for future research on MAIT cells as targets for immunotherapies and vaccines.
Despite the lifesaving success of the COVID-19 vaccines, very rare side effects have emerged. Vaccines engineered from the otherwise-mild adenovirus, for example, have been linked to blood clots. Scientists from Arizona State University, the Mayo Clinic, AstraZeneca and elsewhere have performed simulations on PSC’s Bridges-2 system that suggest simple electrical charge may make a protein involved in blood clot formation stick to particles of the AstraZeneca vaccine. The discovery will be the foundation of an effort to explain how the side effect happens and how the vaccine can be re-engineered to prevent it.
Health care workers who have children under age 5 are twice as likely as other parents to plan to vaccinate their children against COVID-19, according to a new poll conducted by the HERO Registry, which is coordinated by the Duke Clinical Research Institute.
The highly contagious omicron variant of SARS-CoV-2 became the dominant strain in the United States in mid-December 2021, coinciding with a rise in hospitalizations of patients with COVID-19. Among those admitted during the omicron surge, vaccinated adults had less severe illness compared with unvaccinated adults and were less likely to land in intensive care, according to a new study by Cedars-Sinai and the Centers for Disease Control and Prevention (CDC).
New Kaiser Permanente research published February 21, 2022 in Nature Medicine shows that while Moderna COVID-19 vaccine protection is strong against coronavirus infection by the delta variant, it is not as strong against infection from the omicron variant.
There is a slightly elevated risk of intracranial thrombosis events following vaccination with the AstraZeneca ChAdOx1-S COVID vaccine, according to two new studies publishing February 22nd in PLOS Medicine.
Experts at Overlook are hoping that SurVaxM, a first-of-its-kind vaccine targeting a protein found in glioblastomas and other cancers, will give patients a better shot at long-term survival and improved function.
The researchers found that the level of protection from SARS-CoV-2 infection fell by about 21 percentage points, on average, in the interval from one to six months after full vaccination—whereas the level of protection against severe COVID-19 fell by only about 10 percentage points in the same interval.
The Latest Research News in Cardiovascular Health
A new study suggests that a single bout of exercise does not change the immune response to a coronavirus booster shot in people with rheumatic autoimmune diseases. The article is published ahead of print in the Journal of Applied Physiology.
Artificial intelligence has aided one Michigan State University researcher and his team in finding answers about the new omicron variant. The MSU researchers report omicron and other variants are evolving increased infectivity and antibody resistance according to an artificial intelligence model. Therefore, new vaccines and antibody therapies are needed, the researchers say.
The SARS-CoV-2 virus is continuously evolving and structural changes to the virus may impact the efficacy of antibody therapies and vaccines. A study publishing February 17th in PLOS Pathogens by Anshumali Mittal at the University of Pittsburgh, USA and colleagues describes the structural and functional landscape of neutralizing antibodies against SARS-CoV-2 spike protein and discuss the effects of mutations on the virus spike protein that may allow it to evade antibody responses.
Using powerful tools and techniques developed in the field of structural biology, researchers at the University of Washington and The Scripps Research Institute have discovered new details about the human immunodeficiency virus, HIV.
Researchers at Mayo Clinic, along with colleagues in the Netherlands and Germany, may have a viable, less risky alternative to regenerate bone: messenger RNA. This well-known platform for vaccines has already proven to be safe in human use by the FDA.
A future vaccine providing protection against a wide range of coronaviruses that jump from their original animal hosts to humans — including SARS-CoV-2, the cause of COVID-19 — may be possible, say Johns Hopkins Medicine researchers, based on findings from their recent study.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
